Assembly Biosciences (ASMB) Price & Analysis

Compare

565 Followers

ASMB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.75 - $27.17

Previous CloseN/A

Volume7.37K

Average Volume (3M)168.79K

Market Cap

$399.27M

Enterprise Value$66.63M

Total Cash (Recent Filing)$74.98M

Total Debt (Recent Filing)$2.88M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Nov 06, 2025

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.33

Shares Outstanding15,560,009

10 Day Avg. Volume194,163

30 Day Avg. Volume168,792

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.17

Enterprise Value/Revenue2.82

Enterprise Value/Gross Profit2.82

Enterprise Value/Ebitda-1.53

Forecast

1Y Price Target

$39.00

Price Target Upside52.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsLead programs ABI-6250 and ABI-5366 have strong mechanistic validation, favorable pharmacokinetics, and large commercial potential.

CollaborationsAnalyst's Buy rating reflects the potential for Assembly’s clinical-stage antiviral pipeline to deliver significant value in collaboration with Gilead Sciences.

Bears Say

Project DelaysData readout for ABI-5366, originally expected in the first half of 2025, has been delayed to Fall 2025.

Assembly Biosciences News

Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3d ago

Assembly Biosciences initiated with an Outperform at Citizens JMP

Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences (ASMB) with an Outperform rating and $38 price...

3d ago

ASMB

Assembly Biosciences price target raised to $39 from $31 at Guggenheim

Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $39 from $31 and keeps a Buy...

19d ago

ASMB

Four new option listings and one option delisting on August 27th

New option listings for August 27th include Assembly Biosciences (ASMB), CEA Industries Inc (BNC), Dynamix Corp (ETHM), and...

1M ago

BNC

ASMB

Assembly Biosciences assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price...

1M ago

ASMB

Assembly Biosciences Completes $175 Million Equity Financing

Assembly Biosciences ( ($ASMB) ) just unveiled an announcement. On August 8, 2025, Assembly Biosciences announced the pricing...

2M ago

ASMB

Assembly Biosciences Announces Positive Phase 1b Results

Assembly Biosciences ( ($ASMB) ) has provided an announcement. On August 8, 2025, Assembly Biosciences announced positive interim...

2M ago

ASMB

Assembly Biosciences announces pricing of $175M in equity financings

Assembly Biosciences (ASMB) announced the pricing of an underwritten, registered offering of an aggregate of 5,591,840 shares of...

2M ago

ASMB

Assembly Biosciences reports interim results from phase 1b study of ABI-5366

Assembly Biosciences (ASMB) announced positive interim antiviral activity, clinical outcomes, safety and pharmacokinetic results from a Phase 1b...

2M ago

ASMB

GILD

Assembly Biosciences Reports Q2 2025 Progress and Financials

Assembly Biosciences Inc ( ($ASMB) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ASMB

Assembly Biosciences Reports Interim Results for ABI-6250

An update from Assembly Biosciences ( ($ASMB) ) is now available. On August 6, 2025, Assembly Biosciences announced...

2M ago

ASMB

Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179

Assembly Biosciences (ASMB) announced Phase 1a clinical and preclinical data for its herpes simplex virus, HSV, helicase-primase inhibitor...

2M ago

ASMB

Assembly announces first participant dosed in Phase 1b trial of ABI-1179

Assembly Biosciences (ASMB) announced that the first participant has been dosed in the Phase 1b portion of the...

3M ago

ASMB

Assembly Biosciences Reports Positive Phase 1b Trial Results

The latest update is out from Assembly Biosciences ( ($ASMB) ). On June 25, 2025, Assembly Biosciences announced...

3M ago

ASMB

ASMB FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was $7.75 and its highest was $27.17 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is $399.27M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on Aug 06, 2025. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.73 by $0.4.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.82.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 15,560,009 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.73. Following the earnings report the stock price went up 9.213%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in ASMB

Assembly Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-147.64%

Trailing 12-Months

Asset Growth

-29.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences (ASMB) Earnings & Revenues

Historic Earnings Reports

ASMB Stock 12 Month Forecast

Average Price Target

$39.00

▲(52.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.13,26.119999999999997,28.11,30.099999999999998,32.089999999999996,34.08,36.07,38.06,40.05,42.04,44.03,46.019999999999996,48.01,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.13,25.273846153846154,26.417692307692306,27.56153846153846,28.705384615384617,29.84923076923077,30.993076923076924,32.136923076923075,33.28076923076923,34.424615384615386,35.568461538461534,36.71230769230769,37.856153846153845,{"y":39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.13,24.504615384615384,24.87923076923077,25.253846153846155,25.628461538461536,26.00307692307692,26.377692307692307,26.752307692307692,27.126923076923077,27.501538461538463,27.876153846153848,28.25076923076923,28.625384615384615,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.15,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >